Ipilimumab: beside a new treatment under test
229 studies: a new drug, cell therapy or vaccine is what the study tests. Page 2 of 3. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.
- Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01927419Phase 2Results postedReport a problem
- Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)CompletedNCT01840579Phase 1Results postedReport a problem
- NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic MelanomaTerminatedNCT01810016Phase 1Results postedReport a problem
- Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)CompletedNCT01783938Phase 2Results postedReport a problem
- Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaCompletedNCT01740297Phase 1/2Results postedReport a problem
- A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCompletedNCT01714739Phase 1/2Results postedReport a problem
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results postedReport a problem
- PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCompletedNCT01621490Phase 1Results postedReport a problem
- An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results postedReport a problem
- Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaCompletedNCT01585194Phase 2Results postedReport a problem
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedNCT01472081Phase 1Results postedReport a problem
- Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)CompletedNCT01454102Phase 1Results postedReport a problem
- Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaSuspendedNCT06968988Phase 1Report a problem
- Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruitingNCT06784648Phase 1/2Report a problem
- Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®TerminatedNCT06587451Phase 3Report a problem
- A Study to Test the Benefit of Vitamin B5 in Patients With MelanomaActive, not recruitingNCT06377111Phase 1Report a problem
- Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaSuspendedNCT06049576Phase 1Report a problem
- Study of LP-184 in Patients With Advanced Solid TumorsActive, not recruitingNCT05933265Phase 1/2Report a problem
- Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1Report a problem
- Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic CancerCompletedNCT05721846Phase 1Report a problem
- CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid TumorsActive, not recruitingNCT05631899Phase 1Report a problem
- Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingNCT05501054Phase 1/2Report a problem
- Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerWithdrawnNCT05456165Phase 2Report a problem
- A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative NeoplasmsCompletedNCT05444530Phase 1Report a problem
- NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompletedNCT05262556Phase 1Report a problem
- Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsTerminatedNCT05220722Phase 1/2Report a problem
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerActive, not recruitingNCT05141721Phase 2/3Report a problem
- Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaCompletedNCT04988841Phase 2Report a problem
- Fecal Microbial Transplantation Non-Small Cell Lung Cancer and MelanomaActive, not recruitingNCT04951583Phase 2Report a problem
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaTerminatedNCT04935229Phase 1Report a problem
- Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsTerminatedNCT04892043Phase 1Report a problem
- A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.CompletedNCT04855929Phase 1Report a problem
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsSuspendedNCT04840589Phase 1Report a problem
- Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedNCT04787991Phase 1Report a problem
- Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1Report a problem
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)CompletedNCT04495257Phase 1Report a problem
- ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaActive, not recruitingNCT04480502Phase 2Report a problem
- DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1Report a problem
- Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaActive, not recruitingNCT04300244Phase 2Report a problem
- CIML NK Cell in Head & Neck CancerCompletedNCT04290546Phase 1Report a problem
- Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersTerminatedNCT04270864Phase 1Report a problem
- A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Status unknownNCT04250246Phase 2Report a problem
- GVAX Plus Checkpoint Blockade in NeuroblastomaTerminatedNCT04239040Phase 1Report a problem
- Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1Report a problem
- Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell CarcinomaTerminatedNCT04203901Phase 2Report a problem
- Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota TransplantationActive, not recruitingNCT04163289Phase 1Report a problem
- Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaCompletedNCT04133948Phase 1/2Report a problem
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerActive, not recruitingNCT04117087Phase 1Report a problem
- Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsCompletedNCT04084951Phase 1Report a problem
- SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)Active, not recruitingNCT04079166Phase 2Report a problem
- Study of ARRY-614 Plus Either Nivolumab or Nivolumab+IpilimumabActive, not recruitingNCT04074967Phase 1/2Report a problem
- CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnNCT04060407Phase 1/2Report a problem
- Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With MelanomaStatus unknownNCT04021420Phase 1/2Report a problem
- IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMActive, not recruitingNCT04003649Phase 1Report a problem
- Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerCompletedNCT03989362Phase 2Report a problem
- A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedNCT03978611Phase 1Report a problem
- An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersCompletedNCT03956680Phase 1Report a problem
- A Study of a Personalized Cancer Vaccine Targeting Shared NeoantigensCompletedNCT03953235Phase 1/2Report a problem
- Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaCompletedNCT03922880Phase 1Report a problem
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerActive, not recruitingNCT03907852Phase 1/2Report a problem
- Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGGCompletedNCT03879512Phase 1/2Report a problem
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Active, not recruitingNCT03865082Phase 2Report a problem
- CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerCompletedNCT03829111Phase 1Report a problem
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1Report a problem
- Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.Status unknownNCT03784040Phase 1Report a problem
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaActive, not recruitingNCT03769155Phase 1Report a problem
- A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)CompletedNCT03752398Phase 1Report a problem
- Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic NivolumabActive, not recruitingNCT03707808Phase 1/2Report a problem
- VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruitingNCT03690986Phase 1Report a problem
- Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsActive, not recruitingNCT03647163Phase 1/2Report a problem
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedNCT03645928Phase 2Report a problem
- A Study of a Personalized Neoantigen Cancer VaccineCompletedNCT03639714Phase 1/2Report a problem
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedNCT03597282Phase 1Report a problem
- A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaTerminatedNCT03565406Phase 1Report a problem
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedNCT03532217Phase 1Report a problem
- Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCStatus unknownNCT03527251Phase 1Report a problem
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedNCT03526185Early Phase 1Report a problem
- ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid TumorsCompletedNCT03525795Phase 1Report a problem
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3Report a problem
- Combined Immunotherapy and Radiosurgery for Metastatic Colorectal CancerCompletedNCT03507699Phase 1Report a problem
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2Report a problem
- An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedTerminatedNCT03444753Phase 1Report a problem
- Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1Report a problem
- Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaTerminatedNCT03422094Phase 1Report a problem
- CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)CompletedNCT03408587Phase 1Report a problem
- VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerCompletedNCT03373188Phase 1Report a problem
- An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentCompletedNCT03335540Phase 1Report a problem
- Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2Report a problem
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.Active, not recruitingNCT03233152Phase 1/2Report a problem
- Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesActive, not recruitingNCT03233139Phase 1Report a problem
- A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsCompletedNCT03203876Phase 1Report a problem
- A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic MelanomaCompletedNCT03153085Phase 2Report a problem
- Immunotherapy Study of Evofosfamide in Combination With IpilimumabStatus unknownNCT03098160Phase 1Report a problem
- Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1Report a problem
- Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.CompletedNCT02977156Phase 1Report a problem
- NeoVax Plus Ipilimumab in Renal Cell CarcinomaActive, not recruitingNCT02950766Phase 1Report a problem
- Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabCompletedNCT02935790Phase 1Report a problem
- A Study of RGX-104 in Patients With Advanced Lung & Endometrial CancerCompletedNCT02922764Phase 1Report a problem
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02703623Phase 2Report a problem
- Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT02675439Phase 1Report a problem